Das Produkt wurde korrekt in den Warenkorb gelegt.

discount label
H-KASEKIFYV-OH
3D-Ansicht

Biosynth logo

H-KASEKIFYV-OH

Ref. 3D-PP45190

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Voraussichtliche Lieferung in Vereinigte Staaten, am Freitag 27. Dezember 2024

Produktinformation

Name:
H-KASEKIFYV-OH
Synonyme:
  • NH2-Lys-Ala-Ser-Glu-Lys-Ile-Phe-Tyr-Val-OH
Beschreibung:

Peptide H-KASEKIFYV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KASEKIFYV-OH include the following: The use of positional scanning synthetic combinatorial libraries (PS-SCL) to study T Lympohcyte specificity and degeneracy V Rubio-Godoy - 2002 - core.ac.ukhttps://core.ac.uk/download/pdf/18168125.pdf Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity V Rubio-Godoy, M Ayyoub, V Dutoit - European journal of , 2002 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(200208)32:8%3C2292::AID-IMMU2292%3E3.0.CO;2-K Proteasome-Assisted Identification of TRCTLI Metastatic - J Immunol, 2002 - researchgate.nethttps://www.researchgate.net/profile/Danila-Valmori-2/publication/11535787_Proteasome-Assisted_Identification_of_a_SSX-2-Derived_Epitope_Recognized_by_Tumor-Reactive_CTL_Infiltrating_Metastatic_Melanoma/links/5f168594a6fdcc3ed71b36c7/Proteasome-Assisted-Identification-of-a-SSX-2-Derived-Epitope-Recognized-by-Tumor-Reactive-CTL-Infiltrating-Metastatic-Melanoma.pdf Novel TCR-like CAR-T cells targeting an HLA∗ 0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia S Raskin, S Van Pelt, K Toner , PB Balakrishnan - Therapy-Methods & , 2021 - cell.comhttps://www.cell.com/molecular-therapy-family/methods/fulltext/S2329-0501(21)00146-7?elqTrackId=ae3d3c18d29343bda912fab5bc7c9424 Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA S Kreiter , T Konrad, M Sester , C Huber, aca– Tureci - Cancer immunology , 2007 - Springerhttps://link.springer.com/article/10.1007/s00262-007-0302-7 Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals S Kreiter , A Selmi, M Diken , M Sebastian - The Journal of , 2008 - journals.aai.orghttps://journals.aai.org/jimmunol/article/180/1/309/78384 Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma M Ayyoub, S Stevanovic, U Sahin - The Journal of , 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/168/4/1717/34774 Defective Interferon Gamma Production by Tumor-Specific CD8+ T Cells Is Associated With 5'Methylcytosine-Guanine Hypermethylation of Interferon Gamma M Abd Hamid, X Yao, C Waugh - Frontiers in , 2020 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00310/full Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination KA Smith, Z Qiu, R Wong, VL Tam, BL Tam - Cancer Gene , 2011 - nature.comhttps://www.nature.com/articles/cgt201045 227. Efficient Eradication of Castration-Resistant Human Prostate Cancers by Inactivated Sendai Virus Particle K Hatano, Y Kawaguchi, Y Miyamoto, N Nonomura - Molecular Therapy, 2011 - cell.comhttps://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(16)36800-9 SSX expression in gynecological cancers and antibody response in patients K Hasegawa, F Koizumi, Y Noguchi, A Hongo - Cancer Immunity, 2004 - AACRhttps://aacrjournals.org/cancerimmun/article-abstract/4/1/16/472242 Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients J Laurent, DE Speiser , V Appay, C Touvrey - Journal of , 2010 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2010/09000/Impact_of_3_Different_Short_term_Chemotherapy.00009.aspx Cancer-associated antigens and their clinical potential for immunotherapy J Ganapathy , VV Prabhu - Malaya Journal of Biosciences. Journal , 2016 - researchgate.nethttps://www.researchgate.net/profile/Vinod-Prabhu-3/publication/312088973_Cancer-associated_antigens_and_their_clinical_potential_for_immunotherapy/links/586ee12f08ae8fce491ca37a/Cancer-associated-antigens-and-their-clinical-potential-for-immunotherapy.pdf Peptides for vaccine development IW Hamley - ACS Applied Bio Materials, 2022 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/acsabm.1c01238 Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells HA Smith , DG McNeel - Journal of Immunotherapy, 2011 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2011/10000/Vaccines_Targeting_the_Cancer_testis_Antigen_SSX_2.1.aspx The SSX family of cancer-testis antigens as target proteins for tumor therapy HA Smith , DG McNeel - Journal of Immunology Research, 2010 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/full/10.1155/2010/150591 Evaluating the SSX Family of Cancer-Testis Antigens as Immunological Targets for the Treatment of Prostate Cancer H Smith - 1912 - asset.library.wisc.eduhttps://asset.library.wisc.edu/1711.dl/3Q3NIGU7BLH5S84/R/file-6c18f.pdf Development of a T cell receptor targeting an HLA-A* 0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer D Abate-Daga, DE Speiser , N Chinnasamy, Z Zheng - PloS one, 2014 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0093321

Hinweis:
Unsere Produkte sind nur für Laborzwecke. Für jede andere Verwendung, bitte melden sie sich bei uns.
Marke:
Biosynth
Langzeitlagerung:
Hinweise:

Chemische Eigenschaften

MDL:
Schmelzpunkt:
Siedepunkt:
Flammpunkt:
Dichte:
Konzentration:
EINECS:
Merck:
HS-Code:

Gefahrenhinweise

UN-Nummer:
EQ:
Klasse:
H-Sätze:
P-Sätze:
Flugverbot:
Gefahrenhinweis:
Verpackungsgruppe:
LQ:

Technische Anfrage zu: 3D-PP45190 H-KASEKIFYV-OH

Bitte verwenden Sie stattdessen den Warenkorb, um ein Angebot oder eine Bestellung anzufordern

Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.

* Obligatorische felder
Willkommen bei CymitQuimica!Wir verwenden Cookies, um Ihren Besuch zu verbessern. Wir schließen Werbung nicht ein.

Bitte beachten Sie unsere Cookie-Richtlinie  für weitere Details oder passen Sie Ihre Einstellungen unter “Konfigurieren” an.